Clinical Updates in Rheumatoid Arthritis电子书

Faculty: Jonathan Kay, MD

Alan J. Kivitz, MD, CPI

Preamble: Target Audience

Statement of Need/Program Overview

References

Educational Objectives

Physician Accreditation Statement

Physician Credit Designation

Global Contact Information

Instructions to Receive Credit

Fee Information & Refund/Cancellation Policy

Disclosure of Conflicts of Interest

Disclosure of Unlabeled Use

Disclaimer

Chapter 1: Rheumatoid Arthritis Pathophysiology and the Roles of IL-6

Articular and Extra-Articular Disease Manifestations

Factors Contributing to RA Development: A Focus on IL-6

Key Clinical Highlights

References

Chapter 2: Comprehensively Evaluating Patients With Rheumatoid Arthritis

Core Tenets of Treating to Target in RA

Validated Measures of Disease Activity

Additional Evaluation Considerations

Key Clinical Highlights

References

Chapter 3: Biologic Inhibitors of IL-6 Signaling

Tocilizumab

Sarilumab

Key Clinical Highlights

References

Chapter 4: Individualizing Rheumatoid Arthritis Management and the Role of IL-6 Inhibition

Shared Clinical Decision-Making in Rheumatoid Arthritis Management

Positioning Inhibitors of IL-6 Signaling in RA Treatment Algorithms

Key Clinical Highlights

References

Rheumatoid Arthritis Clinical Resource Center™: Guidelines

Patient Resources

American College of Rheumatology Disease Overview

American College of Rheumatology Patient Education Videos

Arthritis Foundation

Handout on Health: Rheumatoid Arthritis

Rheumatoid Arthritis Support Network

Suggested Reading

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.

Measures of rheumatoid arthritis disease activity.

The pathogenesis of rheumatoid arthritis.

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.

Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

CME Posttest